SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
SOPHiA GENETICS (Nasdaq: SOPH) will release fourth-quarter and full-year 2025 financial results before U.S. markets open on March 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) will release fourth-quarter and full-year 2025 financial results before U.S. markets open on March 3, 2026. A conference call to discuss results and business outlook will begin at 8:00 AM EDT / 2:00 PM CET and will be webcast on the company investor relations website. A replay will be available after the call.
Details
News Market Reaction – SOPH
On Feb 17, the day this news came out, SOPH closed 0.21% above the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Earnings release date
- March 3, 2026
- Q4 and full year 2025 results release before U.S. market open
- Quarter reported
- Fourth quarter 2025
- Scheduled financial results to be discussed on March 3, 2026
- Full year reported
- Full year 2025
- Scheduled financial results to be discussed on March 3, 2026
- Conference call time EDT
- 8:00 a.m. EDT
- Start time for earnings conference call
- Conference call time CET
- 2:00 p.m. CET
- Start time for earnings conference call in Europe
Historical Context
-
Signed two major U.S. integrated health systems for SOPHiA DDM platform.
-
Company recognized with six BIG Innovation Awards across product lines.
-
Preliminary Q4/FY 2025 results, 2026 guidance, and executive transition plan.
-
Strategic collaboration with MD Anderson for AI-driven precision oncology.
-
Integration of MSK assays on DNBSEQ-T1+ platform for precision oncology.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform that analyzes complex multimodal data – including genomics, radiomics, clinical, biological, and digital pathology data – to generate real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-announce-financial-results-for-fourth-quarter-and-full-year-2025-on-march-3-2026-302687934.html
SOURCE SOPHiA GENETICS
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.